Genome

NAPIGEN, Inc. Secures U.S. Patent, Awarded USDA SBIR Grant

Retrieved on: 
Monday, March 11, 2024

The patented claims of US11920140 are directed to methods for altering the genomes of mitochondria or plastids.

Key Points: 
  • The patented claims of US11920140 are directed to methods for altering the genomes of mitochondria or plastids.
  • The mitochondria, also known as the powerhouses of cells, are critical components of plant, fungal, algal, and animal cells.
  • It is the third SBIR grant the company has received since its founding in 2016.
  • NAPIGEN, Inc. expects to complete a Series A financing this year to advance partnerships with agricultural companies to bring products to market.

Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma

Retrieved on: 
Monday, March 11, 2024

Syena has an exclusive licensing agreement for MD Anderson’s TCR-NK technology platform.

Key Points: 
  • Syena has an exclusive licensing agreement for MD Anderson’s TCR-NK technology platform.
  • This first-in-class engineered cell therapy comprises cord blood-derived natural killer cells that express an affinity-enhanced TCR targeted against the NY-ESO-1 antigen.
  • The Phase 1/2 clinical study will assess the safety and efficacy of NY-ESO-1 TCR/IL-15 NK in patients with relapsed or refractory multiple myeloma.
  • NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma, making this a suitable indication for demonstrating proof of concept for Syena’s TCR-NK technology platform.

Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024

Retrieved on: 
Tuesday, March 5, 2024

Total revenue for the fourth quarter of 2023 was $10.7 million, an increase of 30% compared to the fourth quarter of 2022.

Key Points: 
  • Total revenue for the fourth quarter of 2023 was $10.7 million, an increase of 30% compared to the fourth quarter of 2022.
  • GAAP gross margin for the fourth quarter of 2023 was 23%, which was slightly higher than the 22% GAAP gross margin reported for the fourth quarter of 2022.
  • Fourth quarter 2023 GAAP operating expense was $27.4 million, compared to $39.3 million in the fourth quarter of 2022.
  • Fourth quarter 2023 non-GAAP operating expense was $27.3 million, compared to $30.6 million in the fourth quarter of 2022.

GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024

Retrieved on: 
Tuesday, February 20, 2024

ET

Key Points: 
  • ET
    STAMFORD, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported its financial results for the fourth quarter and full year of 2023.
  • Exome and genome represented 27% of all test results, up from 16% in the fourth quarter of 2022 and up from 23% in the third quarter of 2023.
  • Adjusted gross margin from continuing operations expanded to 56%, up from 41% in the fourth quarter of 2022 and up from 48% in the third quarter of 2023.
  • Excluding one-time items, representative continuing operations cash burn was $23.9 million in the fourth quarter of 2023.

Asia-Pacific Rare Disease Genetic Testing Market Analysis and Forecasts, 2023-2024 and 2033 - Opportunities in Transitioning Toward Increased Genetics Coverage in Reimbursement Policies - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 7, 2024

The "Asia-Pacific Rare Disease Genetic Testing Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia-Pacific Rare Disease Genetic Testing Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The Asia-Pacific (APAC) rare disease genetic testing market is witnessing notable growth driven by various factors.
  • What are the major market drivers, challenges, and opportunities in the Asia-Pacific rare disease genetic testing market?
  • What are the key development strategies implemented by the key players to stand out in the Asia-Pacific rare disease genetic testing market?

Revolutionary Elephant iPSC Milestone Reached in Colossal’s Woolly Mammoth Project

Retrieved on: 
Wednesday, March 6, 2024

Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced pluripotent stem cells) breakthrough.

Key Points: 
  • Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced pluripotent stem cells) breakthrough.
  • This milestone advancement was one of the primary early goals of the mammoth project, and supports the feasibility of future multiplex ex utero mammoth gestation.
  • Invaluable for Colossal’s Woolly Mammoths, these cells can be multiplex-edited and differentiated to study cold adaptation traits like woolly hair growth and fat storage in cellular and organoid models.
  • “In the past, a multitude of attempts to generate elephant iPSCs have not been fruitful.

Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing

Retrieved on: 
Tuesday, March 5, 2024

The suite of our CE-marked Products includes:

Key Points: 
  • The suite of our CE-marked Products includes:
    The Twist Precision Prep and Enrichment Dx Kit1 (Reagents for enzymatic fragmentation, library preparation, and target enrichment), which is panel-agnostic2
    Twist Precision Exome Dx Kit1 (Reagents for enzymatic fragmentation, library preparation, and target enrichment along with targeted capture probes for exome enrichment; IVDR compliant workflow)
    The Twist Precision Prep and Enrichment Dx Kit and the Twist Precision Exome Dx Panel can be used individually within existing workflows or as a combined solution known as the Twist Precision Exome Dx Kit.
  • “The Twist Precision Dx products are our first NGS product line specifically developed to be included within regulated customer products.
  • The Twist Precision Exome Dx Panel1 is a qualified Twist DNA panel that can be used in conjunction with the Twist Precision Prep and Enrichment Dx kit to produce exome-enriched libraries compatible for NGS applications.
  • Twist Precision Exome Dx Kit1 utilizes the qualified Twist Precision Exome Dx Panel along with the Twist Precision Prep and Enrichment Dx Kit to produce exome-enriched libraries compatible for NGS applications.

Global Metagenomic Market Research 2024-2028: A Game Changer in Diagnostics - New Technology Changes Viewpoint on Infections - ResearchAndMarkets.com

Retrieved on: 
Friday, March 1, 2024

The "Metagenomic Markets: Global Market Analysis with Forecasts by Applications, Technologies, Product and User 2024 to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Metagenomic Markets: Global Market Analysis with Forecasts by Applications, Technologies, Product and User 2024 to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Learn all about it in this new research report.
  • This report looks at the technology, the applications, the users and the types of products that will be sold.
  • Get our research team working for you by ordering all, or a portion, of this comprehensive report.

European UPC Court of Appeal Overturns Injunction Impacting NanoString’s CosMx Products, Company to Immediately Resume Sales in 16 EU Countries

Retrieved on: 
Monday, February 26, 2024

The decision allows NanoString to immediately resume sales of all CosMx products in 16 impacted UPC member countries.

Key Points: 
  • The decision allows NanoString to immediately resume sales of all CosMx products in 16 impacted UPC member countries.
  • “We believe that with today’s decision, the tide is turning in favor of NanoString and scientific freedom.
  • NanoString is evaluating its next steps in Germany in light of today’s decision from the UPC and for now the German injunction remains in place.
  • The CosMx SMI platform has been installed at approximately 180 customer sites to date.

Comprehensive Study from 50 Top Scientists Details Five Cutting-edge Advances in Biomedical Engineering and Their Applications in Medicine

Retrieved on: 
Thursday, February 22, 2024

Through the course of the workshop, the researchers identified five primary medical challenges that have yet to be addressed, but, by solving them with advanced biomedical engineering approaches, can greatly improve human health.

Key Points: 
  • Through the course of the workshop, the researchers identified five primary medical challenges that have yet to be addressed, but, by solving them with advanced biomedical engineering approaches, can greatly improve human health.
  • By focusing on these five areas, the consortium has laid out a roadmap for future research and funding.
  • Advanced technologies, such as wearable sensors and digital twins, can provide the basis of a solution to this challenge.
  • Despite the rapid advances in genomics in the past few decades, there are obstacles remaining in our ability to engineer genomic DNA.